zyprexa.jpegEli Lilly and the Department of Justice reached a series of settlements resulting from illegal marketing, defrauding the government, and making false claims related to Zyprexa. The company will pay more than $1.4 billion (including a criminal fine of $515 million) for a scheme that broadly affected patient health, government spending and the credibility of federal regulatory agencies. A five-year corporate integrity agreement specifying reporting, written standards, and tracking of information, was part of the settlement.

Post a Comment

MIWatch would love to hear your thoughts. Please join the discussion.

characters left